GSK Submits Application to Expand Indication for FluLaval Flu Vaccine
February 02 2016 - 9:44AM
Dow Jones News
LONDON--GlaxoSmithKline PLC (GSK.LN) has submitted a
supplemental Biologics License Application to the U.S. Food and
Drug Administration for its influenza vaccine Flulaval
Quadrivalent.
The healthcare company said Tuesday that the vaccine is
currently approved for active immunisation against influenza A
subtype viruses and type B viruses, in persons three years of age
and older.
The submission seeks an expanded indication for children six
months through 35 months of age, it said.
GlaxoSmithKline shares at 1410 GMT down 8 pence, or 0.5%, at
GBP14.27, valuing the company at GBP69.54 billion.
-Write to Razak Musah Baba at razak.baba@wsj.com; Twitter:
@Raztweet
(END) Dow Jones Newswires
February 02, 2016 09:29 ET (14:29 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
